title: Determinants of direct costs in Dutch rheumatoid arthritis patients.
abstract: OBJECTIVE
  To estimate annual direct costs in four distinct disease duration groups (0 to < or =2, 2 to < or =6, 6 to < or =10, and >10 years) of patients with rheumatoid arthritis (RA), to determine predictors of high costs and to describe characteristics of patients with high and with low costs.
  
  
  METHODS
  A questionnaire assessing RA related care and resource utilisation rates and costs was completed by 615 RA patients. Predictive variables for incurred costs, as observed during the first year after disease onset, were determined in a subgroup of patients (n = 347).
  
  
  RESULTS
  Mean (median) annual direct costs for the four groups with increasing disease duration were respectively: 5235 (2923) Euros, 3930 (1968) Euros, 4664 (1952)Euros, and 8243 (3778) Euros, (p < 0.05). During the first 2 years of the disease total direct costs comprised mainly of consultations with healthcare workers (28%). After 10 years, devices and adaptations were the main contributors (40%) to total costs. Positive rheumatoid factor results at the time of diagnosis and deterioration of functional disability in the first year of disease were predictors of high costs later on in the course of the disease.
  
  
  CONCLUSIONS
  Annual direct costs among patients with a disease duration of less than 2 years tend to be lower among patients with a disease duration of between 2 and 10 years than among patients with a disease duration of more than 10 years. In addition, the proportional distribution of different cost categories to total costs increases with with increasing disease duration.
authors.affiliation: University Medical Center Utrecht, Department of Rheumatology and Clinical Immunology, F02.127, PO Box 85500, 3508 GA Utrecht, The Netherlands. s.verstappen@azu.nl
authors.forename: S M M
authors.initials: SM
authors.lastname: Verstappen
authors.forename: H
authors.initials: H
authors.lastname: Verkleij
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: E
authors.initials: E
authors.lastname: Buskens
authors.forename: A A
authors.initials: AA
authors.lastname: Kruize
authors.forename: A H M
authors.initials: AH
authors.lastname: Heurkens
authors.forename: M J
authors.initials: MJ
authors.lastname: Van Der Veen
authors.forename: J W G
authors.initials: JW
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000191:economics* / Q000628:therapy; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D004180:Direct Service Costs; D018450:Disease Progression; D004864:Equipment and Supplies / Q000191:economics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D012017:Referral and Consultation / Q000191:economics; D012217:Rheumatoid Factor / Q000097:blood; D012219:Rheumatology / Q000191:economics; D011795:Surveys and Questionnaires
chemical_list: D012217:Rheumatoid Factor